A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro

Cardiotoxicity is the main dose-limiting side effect of doxorubicin in the clinic. Being a free radical producer, doxorubicin affects the heart specifically because of its low antioxidant capacity. Among those antioxidants, catalase is present in very low levels in the heart compared to other organs...

Descripción completa

Detalles Bibliográficos
Autores principales: Abou El Hassan, M A I, Rabelink, M J W E, van der Vijgh, W J F, Bast, A, Hoeben, R C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376857/
https://www.ncbi.nlm.nih.gov/pubmed/14647150
http://dx.doi.org/10.1038/sj.bjc.6601430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376857/
https://www.ncbi.nlm.nih.gov/pubmed/14647150
http://dx.doi.org/10.1038/sj.bjc.6601430

Ejemplares similares